Pamidronate Disodique Hospira (Pamidronate Disodium)

Pamidronate Disodium, the active ingredient in Pamidronate Disodique Hospira, is a bisphosphonate presented as an injectable solution for intravenous use. It is used to treat disorders of bone metabolism, particularly in patients with cancer‑related bone disease and in those requiring calcium management after parathyroid surgery. GNH USA supplies Pamidronate Disodique Hospira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

GNH USA supplies Pamidronate Disodique Hospira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Pamidronate Disodium is indicated for several bone‑related conditions that involve excessive bone turnover.

- Hypercalcaemia of malignancy: helps reduce elevated calcium levels caused by cancer. - Osteolytic bone metastases: slows the progression of bone lesions and reduces skeletal‑related events. - Paget’s disease of bone: normalises bone remodeling and alleviates pain. - Prevention of hypocalcaemia after parathyroidectomy: stabilises calcium levels post‑surgery. - Hypercalcaemia associated with hyperparathyroidism: assists in lowering serum calcium. - Bone pain associated with multiple myeloma: provides analgesic benefit through bone turnover reduction.

Adverse reactions to pam­...

Common Side Effects: - Nausea - Fever - Musculoskeletal mus  - Flushing  - Transient elevated blood pressure -  

Serious or Rare ":  -  t .

t ".

Pamidronate  g .

  " ".

  .

  t .